

# Jon Weidanz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9314967/publications.pdf>

Version: 2024-02-01

7  
papers

138  
citations

1478505

6  
h-index

1720034

7  
g-index

10  
all docs

10  
docs citations

10  
times ranked

250  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Single-Domain TCR-like Antibody Selective for the Qa-1b/Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint. <i>Journal of Immunology</i> , 2022, 208, 2246-2255.	0.8	1
2	Targeting cancer with bispecific antibodies. <i>Science</i> , 2021, 371, 996-997.	12.6	15
3	TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. <i>MAbs</i> , 2017, 9, 603-614.	5.2	23
4	An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer. <i>Journal of Immunology</i> , 2011, 186, 6607-6616.	0.8	17
5	Biochemical Mechanism of Acetaminophen (APAP) Induced Toxicity in Melanoma Cell Lines. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1409-1425.	3.3	30
6	Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. <i>Expert Review of Proteomics</i> , 2006, 3, 641-652.	3.0	15
7	A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 345-357.	4.2	37